Table 1 Characteristics of included studies in meta-analysis
| Â | Van Belle et al [11] | Lee et al [12] | Liu et al [13] | Alkhalil et al [14] | Castro-Meija et al [15] | Banerjee et al [16] | Hoshino et al [17] |
|---|---|---|---|---|---|---|---|
Publication Year | 2020 | 2019 | 2016 | 2020 | 2022 | 2021 | 2020 |
Follow up duration (years) | 1 | 1 | 3 | 4 | 4 | 5 | 5 |
Trial Design | Prospective cross-sectional study | Post-hoc analysis of RCT | Prospective Registry | Prospective cross-sectional study | Retrospective open-label | Prospective Cohort Study (sub-group analysis) | Pooled analysis of 3 prospective registries (sub-group analysis) |
Pressure wire modality and threshold for deferred revascularisation * | FFR > 0.8 | FFR > 0.8; iFR > 0.89 | FFR > 0.8 | FFR > 0.8 | FFR > 0.8; iFR > 0.89 | FFR > 0.75 | FFR > 0.75 |
Number of patients | 958 | 579 | 512 | 860 | 434 | 53 | 879 |
Primary Outcome | MACE | MACE | MACE | MACE** | MACE | MACE | MACE |
% Diabetic | 30.9% | 30.6% | 27% | 18.5% | 35.3% | 52.8% | 33.6% |
Indication for physiology | Stable disease (75.3%); Current or recent ACS (24.7%) | Stable disease (81.2%) | Stable disease (60%) | N/A | Stable disease (35.6%); non-culprit vessel in ACS (33.3%); Unstable angina (20%) | Stable disease (100%) | Stable disease or ACS non-culprit vessel |
% Male | 72.3% | N/A | 57% | 74% | 76.5% | N/A | N/A |
Mean Age | 66.3 | N/A | 66.9 | 66 | N/A | N/A | N/A |
Mean FFR | 0.89 ± 0.05 | N/A | N/A | 0.88 (0.84–0.91) | 0.87 ± 0.46 | N/A | N/A |